03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Uromitexan Injectable 5g* : | |
Type | Medicine Non Marketed |
Originator | B |
Agent | Abela Freres |
Distributor | Abela Freres |
Laboratory | Baxter |
Responsible Party | Asta Medica AG |
Origin | Germany |
Manufacturer | Asta Medica AG |
Origin | Germany |
ATC | V03AF01 |
Revision Date | 01/01/2002 |
Uromitexan Injectable 5g* :
Uromitexan Injectable 5g* :
Uromitexan Injectable 5g* :
Uromitexan Injectable 5g* :
Uromitexan Injectable 5g* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Very Common |
Activated partial thromboplastin time prolonged | Not known |
Anaphylaxis | Not known |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Not known |
Arthralgia (Pain joint) (Joint ache) | Common |
Asthenia | Not known |
Back pain | Common |
Blistering | Not known |
Bronchospasm | Common |
Bullae | Not known |
Burning sensation | Not known |
Chest pain | Common |
Conjunctivitis | Common |
Constipation | Common |
Cough | Common |
Decreased appetite | Common |
Dehydration | Common |
Diarrhoea (Diarrhea) | Very Common |
Dizziness | Common |
Drowsiness | Very Common |
Drug eruption | Not known |
Dry mouth (Xerostomia) | Common |
Dyspnoea (dyspnea) | Common |
Dysuria (Micturition painful) | Common |
Epigastralgia (Epigastric pain) | Common |
Epigastric burning | Common |
Epistaxis (Nasal bleeding) | Common |
Erythema | Not known |
Erythema multiforme | Not known |
Face oedema | Not known |
Fatigue | Common |
Flatulence | Common |
Flushing | Very Common |
Gingival bleeding (Gingival hemorrhage) | Common |
Headache | Very Common |
Hyperaesthesia | Common |
Hyperhidrosis | Common |
Hypersensitivity | Not known |
Hypoesthesia | Common |
Hypotension | Not known |
Hypoxia | Not known |
Impairment of attention | Common |
Influenza-like illness | Very Common |
Infusion site erythema | Common |
Infusion site pain | Common |
Infusion site pruritus | Very Common |
Infusion site rash | Very Common |
Infusion site reactions | Very Common |
Infusion site swelling | Common |
Infusion site urticaria | Common |
Insomnia | Common |
Jaw pain | Common |
Laryngeal discomfort | Common |
Lethargy | Very Common |
Lightheadedness | Very Common |
Lymphadenopathy | Common |
Malaise | Common |
Mucosal irritation | Common |
Myalgia | Common |
Nasal congestion | Common |
Nausea | Very Common |
Nightmares | Common |
Oedema peripheral | Not known |
Pain in extremity (Pain in limb) | Common |
Palpitations | Common |
Paraesthesia (paresthesia) | Common |
Photophobia | Common |
Pleuritic pain | Common |
Pruritus | Common |
Pyrexia | Very Common |
Renal failure acute (Acute renal insufficiency) (Kidney failure acute) (Renal insufficiency acute) | Not known |
Respiratory distress | Not known |
Rigors | Common |
Skin rash | Very Common |
Syncope | Common |
Tachycardia | Not known |
Transaminases increased | Common |
Urticaria | Not known |
Vision blurred | Common |
Vomiting | Common |
Uromitexan Injectable 5g* :
NB : Products With Same Indication |
Different Units By MoH Code
Uromitexan Injectable 5g* MoH 11 :
Form | Solution for injection |
Packaging | Bottle |
Package Size | 50ml |
Strength | 5g |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 38922 |
Submission date | 01/01/1993 |
Registration Year | 1993 |
Archived Date | 2014 |
Price Comparison
● Country: | Finland |
● Package Size: | 1x50ml |
● Reference: | Kela |
● Pricing Date: | 22/04/2021 |
● Type: | Medicine Non Marketed |
● Country: | France |
● Package Size: | 1x50ml |
● Reference: | ansm |
● Pricing Date: | 15/05/2021 |
● Type: | Medicine Authorised |
You have to register to view this info
Drop File